Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides

Adagio Therapeutics · 2022-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

19
every slide · same image gating as the playbook
01
Slide 1
The logo uses a molecular structure motif.front_matter
03
The slide serves as a corporate overview or 'about us' summary.summarize
04
The chart is a visualization of viral evolution over time, highlighting the rapid succession of dominant variants.diagnose_problem
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
05
The slide uses a phylogenetic tree and a dot plot to compare neutralization potency (IC50) across different viral strains.compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
06
The slide contrasts cocktail-based strategies (colored dots) with a single broadly neutralizing antibody (black dots) against various SARS-related coronavirusesanalyze_data
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
07
The slide uses a heatmap to visualize IC50 values, where red indicates higher potency (lower IC50).compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
08
The table uses a color-coded heatmap to represent IC50 values, with red indicating higher potency (lower IC50).compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
09
The slide includes a disclaimer about the lack of head-to-head trials and the investigational status of ADG20.analyze_data
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
10
The table uses color-coding to represent IC50 potency, with red indicating higher potency (lower IC50) and grey indicating lower potency.analyze_data
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
11
The table uses a color-coded scale to represent potency (IC50), where red indicates higher potency (lower IC50) and white/grey indicates lower potency.compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
12
The slide includes a disclaimer about the lack of head-to-head trials and the investigational status of ADG20.compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
13
The table uses a color-coded scale to represent IC50 potency, with red indicating high potency (low IC50) and grey indicating low potency (high IC50).compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
14
The table uses a color-coded heatmap where red indicates higher potency (lower IC50 values) and yellow/white indicates lower potency. Includes disclaimers aboutcompare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
15
The slide uses a process flow diagram to illustrate clinical trial cohorts, randomization, and primary endpoints.present_framework
Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done
16
The slide uses a clean, list-based layout to communicate R&D and clinical strategy.present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done
17
The chart uses a logarithmic scale for the x-axis and includes a trend line with a confidence interval (yellow shaded area).analyze_data
Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done
18
present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done
19
introduce_nominees